Abstract
High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN) is now ending its second decade as an established modality for treating Parkinson's disease (PD). Knowledge of the pathophysiology of PD and clinical applications for STN DBS is burgeoning. Despite this, the mechanism of how STN DBS works remains an enigma. Furthermore, motor symptoms have been seen as a focus for improved quality of life after STN DBS yet non-motor symptoms also play an integral role in determining treatment outcome. In this paper, new evidence for the mechanisms of action of STN DBS is discussed and the impact of the therapy on motor and non-motor symptoms of PD is analysed. Future directions of treatment and emerging technologies are also reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
